Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week Examines How Amarin Reeled In A Partner For Vascepa

Executive Summary

Amarin signed Kowa Pharmaceuticals America as a commercial partner for its fish oil pill, more than doubling the number of sales reps detailing the medicine. Forma signed a second drug discovery pact with Celgene, while Baxter bolstered its hemophilia franchise by buying out partner Chatham Therapeutics.

You may also be interested in...



Amarin Making The Best Of Vascepa As Battle Continues With FDA

The biotech has been making lemonade of its fight with FDA for expanded use of its fish-oil drug Vascepa by upping its promotion of the current indication, but executives continue to sound pessimistic about winning over the agency.

AstraZeneca’s Epanova: Third In Omega-3 Market, Potentially First With Larger Population Claim

Fish oil treatment is the first to offer a dosing regimen of as few as two capsules, once a day, with our without food, AstraZeneca said.

As Baxter Embarks On A New Course, It Bolsters Its Hemophilia Franchise

While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel